Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18680910 | ANTI-NPR1 ANTIBODIES AND USES THEREOF | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17687051 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18251913 | ANTIBODY Fc VARIANTS | Non-Final OA | Novartis AG |
| 18187242 | USE OF CANAKINUMAB | Non-Final OA | Novartis AG |
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | Final Rejection | Novo Nordisk A/S |
| 18042553 | Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18011884 | TREATING RHEUMATOID ARTHRITIS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17914000 | BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18338855 | Nanopore Biosensors and Uses Thereof | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18010888 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | Non-Final OA | Acceleron Pharma Inc. |
| 18638633 | STABLE LIQUID FORMULA | Non-Final OA | CELLTRION INC. |
| 18296296 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | Non-Final OA | Gilead Sciences, Inc. |
| 17594730 | ENHANCEMENT OF FIBROBLAST THERAPEUTIC ACTIVITY BY T CELL MODULATION | Non-Final OA | Figene, LLC |
| 18030733 | NOTCH4 ANTIBODIES AND USES THEREOF | Non-Final OA | The Children's Medical Center Corporation |
| 17631034 | USE OF DRUG IN INHIBITING THE PRODUCTION AND MATURATION OF RED BLOOD CELLS | Non-Final OA | SOOCHOW UNIVERSITY |
| 18613481 | METHODS OF TREATING AN IL-5 MEDIATED DISEASE BY ADMINISTERING AN IL-5 BINDING PROTEIN | Non-Final OA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 17768053 | AN ANTIBODY, A PHARMACEUTICAL COMPOSITION, AND A METHOD | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 17971477 | BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION | Non-Final OA | Loyola University of Chicago |
| 18264013 | METHODS AND MATERIALS FOR IMPROVED IMMUNOASSAYS USING SYNTHETIC ANTIGENS | Non-Final OA | THE TERASAKI INNOVATION CENTER |
| 18034167 | BCMA-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF | Non-Final OA | BIOHENG THERAPEUTICS LIMITED |
| 18343087 | PHARMACEUTICAL FORMULATION FOR TREATMENT OF CEREBRAL STROKE | Non-Final OA | PHARMAZZ, INC. |
| 17924496 | COMBINATION THERAPY FOR TTR AMYLOIDOSIS | Non-Final OA | Neurimmune AG |
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | Non-Final OA | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS |
| 18265223 | ANTI-HUMAN B7-H3 ANTIBODY AND APPLICATION THEREOF | Non-Final OA | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. |
| 18002229 | Method for determining potency of chimeric antigen receptor expressing immune cells | Non-Final OA | CELLECTIS S.A. |
| 18245533 | ALPHA-SYNUCLEIN VACCINE FOR THE TREATMENT OF SYNUCLEINOPATHIES | Non-Final OA | PROTHENA BIOSCIENCES LIMITED |
| 18026185 | METHOD OF TREATING AMYLOIDOSIS | Non-Final OA | Caelum Biosciences, Inc. |
| 17819465 | AGENT FOR USE IN THE TREATMENT AND PROPHYLAXIS OF POSTISCHEMIC TISSUE INJURY | Final Rejection | Julius-Maximilians-Universität Würzburg |
| 17818885 | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Bioverativ USA Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy